Tacrolimus Combined with Methylprednisolone in the Treatment of Lupus Nephritis and Its Effect on SLEDAI Score

  • Liangyu Fei
Keywords: Tacrolimus; Methylprednisolone; Lupus nephritis; Urinary protein

Abstract

This paper discusses the efficacy and safety of tacrolimus combined with methylprednisolone in the treatment of
lupus nephritis. 64 patients with lupus nephritis were divided into study group and control group, 32 cases in
each group. The study group was treated with tacrolimus and methylprednisolone, while the control group was
treated with cyclophosphamide and methylprednisolone. The remission rate and adverse reactions were
compared between the two groups. The results showed that the therapeutic effect of the study group was
significantly better than that of the control group; the 24-hour urine protein quantity, serum creatinine (SCR),
systemic lupus erythematosus disease activity index (SLEDAI) scores of the two groups were significantly
reduced, C3, ALB were significantly increased, the difference was statistically significant (P<0.05); after
treatment, the 24-hour urine protein quantity and SLEDAI scores of the study group were significantly lower
than that of the control group, SCR, ALB, ALB, ALB, SCR, ALB, ALB, ALB. C3 and ALB were significantly
higher than those in the control group, and the incidence of adverse reactions in the study group (14%) was
significantly lower than that in the control group (38%). Tacrolimus combined with methylprednisolone in the
treatment of lupus nephritis is effective, can significantly reduce the level of urine protein, effective control of
the disease, and high safety.

Published
2020-03-01